Shire's $2.4M Fee Bid In Adderall Row Too High, Rival Says
Shire PLC is trying to overbill a generic competitor with a $2.38 million fee request after winning a patent infringement suit over its popular hyperactivity treatment Adderall XR, Shire's competitor told...To view the full article, register now.
Already a subscriber? Click here to view full article